ß2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells.
ß2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells. J Allergy Clin Immunol. 2015 Jan; 135(1):290-1.